RecruitingEarly Phase 1NCT07072611

Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

A Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

Sponsor

Noxopharm Limited

Enrollment

32 participants

Start Date

Jul 14, 2025

Study Type

INTERVENTIONAL

Conditions

Cutaneous Lupus Erythematosus

Summary

The goal of this study is to investigate the safety and tolerability of the topical application of SOF-SKN in healthy volunteers. The study will be divided into part 1 and part 2. Part 1, is a single ascending dose (SAD) design, while Part 2 is a multiple ascending dose (MAD) design.

Eligibility

Min Age: 18 YearsMax Age: 64 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo, a drug called SOF-SKN 0.25%, and others for people with cutaneous lupus erythematosus. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSOF-SKN 0.25%

cream for topical application

DRUGSOF-SKN 0.5%

cream for topical application

DRUGSOF-SKN 1%

cream for topical application

DRUGSOF-SKN 2%

cream for topical application

DRUGPlacebo

cream for topical application

Locations(1)

Doherty Clinical Trials

Melbourne, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07072611

Related Trials

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT0735521813 locations

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737272 locations

Deep Phenotyping of Cutaneous Lupus Erythematosus

NCT064111061 location